Repositioning Candidate Details
| Candidate ID: | R0786 |
| Source ID: | DB05410 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | NCX 1022 |
| Synonyms: | -- |
| Molecular Formula: | C29H35NO9 |
| SMILES: | CC12CC(O)C3C(CCC4=CC(=O)CCC34C)C1CCC2(O)C(=O)COC(=O)C1=CC=CC(CON(=O)=O)=C1 |
| Structure: |
|
| DrugBank Description: | NCX is an NO-releasing derivative of hydrocortisone. |
| CAS Number: | 571186-50-0 |
| Molecular Weight: | 541.597 |
| DrugBank Indication: | Investigated for use/treatment in atopic dermatitis. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | NCX 1022 is designed to have potent anti- inflammatory activity combined with a significantly improved safety and tolerability profile, in particular the absence of skin blanching after repeated use.It is better than hydrocortisone in terms of inhibiting benzalkonium chloride-induced leukocyte adhesion to the endothelium, without affecting the flux of rolling leukocytes or venule diameter. |
| Targets: | -- |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|